ALNY News 65.34 08/14/2014 04:31:02 Alnylam Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alnylam Pharmaceuticals (ALNY) 65.34 $ALNY

Alnylam's Q2 Loss Wider-than-Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:40AM CDT
Alnylam Pharmaceuticals Inc.'s (ALNY) second quarter 2014 loss of 63 cents per share was wider than the Zacks Consensus Estimate of a loss of 54 cents.

Alnylam Pharmaceuticals Reports Second Quarter 2014 Financial Results and Highlights Recent Period Activities
Business Wire - Thu Aug 07, 3:00PM CDT
--- Reported Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, Demonstrating Statistically Significant Knockdown of Antithrombin (AT) and Increase in Thrombin Generation -

The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast "ALN-PCSsc for the Treatment of Hypercholesterolemia"
Business Wire - Thu Aug 07, 8:43AM CDT
The Medicines Company (NASDAQ:MDCO) today announced that in collaboration with Alnylam Pharmaceuticals (NASDAQ:ALNY) it will be hosting the "ALN-PCSsc for the treatment of Hypercholesterolemia" RNAi Roundtable webcast on August 14, 2014. Event details are below.

Alnylam Receives Orphan Drug Designations in the European Union for ALN-AT3, an RNAi Therapeutic in Development for the Treatment of Hemophilia
Business Wire - Thu Aug 07, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designations for ALN-AT3 as an orphan medicinal product for the treatment of hemophilia A and hemophilia B. Alnylam is developing ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT), for the treatment of hemophilia and other Rare Bleeding Disorders (RBD).

Alnylam Pharmaceuticals Down 13.8% Since SmarTrend Downtrend Call (ALNY)
Comtex SmarTrend(R) - Mon Aug 04, 9:50AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 1 month, Alnylam Pharmaceuticals has returned 13.81% as of today's recent price of $53.76.

Sanofi Beats on Q2 Earnings, View Up on Strong Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 8:10AM CDT
Sanofi (SNY) reported second quarter 2014 business earnings of 80 cents per American Depositary Share.

Biotech Stock Mailbag: Arrowhead, Catalyst Pharma
at The Street - Fri Aug 01, 7:06AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.

Alnylam to Webcast Conference Call Discussing Second Quarter 2014 Financial Results
Business Wire - Thu Jul 31, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the second quarter ending June 30, 2014 on Thursday, August 7, 2014, after the U.S. financial markets close.

Alnylam to Host Additional Events in "RNAi Roundtable" Webcast Series
Business Wire - Tue Jul 29, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has added three new events to its series of online "RNAi Roundtables" that it is hosting during July and August. Each event will be webcast live on the Investors section of the company's website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.

Downtrend Call Working As Alnylam Pharmaceuticals Stock Falls 13.2% (ALNY)
Comtex SmarTrend(R) - Mon Jul 28, 9:21AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 1 month, Alnylam Pharmaceuticals has returned 13.21% as of today's recent price of $54.13.

Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Conjugate-Based Delivery of RNA Therapeutics
Business Wire - Tue Jul 22, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Manoharan et al. patent application 13/693,478. The '478 patent application includes newly allowed claims directed to compositions including those comprising a modified RNA agent linked to a biantennary or triantennary ligand. Specifically, the allowed application includes claims that broadly cover single-stranded or double-stranded, chemically modified RNA therapeutics conjugated with an N-acetylgalactosamine (GalNAc) ligand independent of length, sequence, or disease target. The allowance of this patent application represents a major advance in Alnylam's intellectual property (IP) estate, since GalNAc-siRNA conjugates enable potent and durable silencing of liver-expressed disease genes with subcutaneous dose administration and a wide therapeutic index. Importantly, this delivery approach is a key component of the company's execution on its "Alnylam 5x15" and broader genetic medicine product strategy.

Shares of ALNY Down 14.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Jul 16, 9:14AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 3 weeks, Alnylam Pharmaceuticals has returned 14.81% as of today's recent price of $53.13.

What RXi Pharmaceuticals' Move to the Russell Microcap Index Means
ACCESSWIRE - Wed Jul 09, 8:48AM CDT
WHITEFISH, MT / July 9, 2014 / RXi Pharmaceuticals Corp. (NASDAQ: RXII), a biotechnology company focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently began trading on the Russell Microcap index on June 27, 2014. Membership on the index remains for one year and is based on market cap and style attributes.

Patient Enrollments, Board Appointments, Acquisitions, and Technical Updates - Analyst Notes on Questcor, Synta, Clovis, Alnylam and Intrexon
PR Newswire - Tue Jul 08, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Clovis Oncology, Inc. (NASDAQ: CLVS), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Intrexon Corporation (NYSE: XON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4522-100free.

Growth and Dividends: Europe's Best Pharma Stock
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jul 07, 4:00PM CDT
This stock is making smart investments in biotech -- and not just through partnerships, but through actual equity investments in biotechs like  Regeneron  and  Alnylam Pharmaceuticals  . It's a smart play for income investors (3.5% dividend yield)...

Alnylam to Host "RNAi Roundtable" Webcast Series
Business Wire - Mon Jul 07, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast a series of online "RNAi Roundtables" during July and August. Alnylam scientists and key clinical collaborators will review recent progress from several of the "Alnylam 5x15" programs and discuss the related disease areas. Each event will be webcast live on the Investors section of the company's website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.

Alnylam Elects Amy Schulman to its Board of Directors
Business Wire - Wed Jul 02, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the election of Amy W. Schulman to its Board of Directors. Ms. Schulman is the former Executive Vice President and General Counsel of Pfizer Inc., and served as the Business Unit Lead for Pfizer's Consumer Healthcare business. She currently serves on the faculty of Harvard Business School as a Senior Lecturer.

Alnylam Added to Russell 1000 Index as a Member of the Large-Cap Segment of the U.S. Equity Universe
Business Wire - Mon Jun 30, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has been added to the Russell 1000 Index, effective June 27, 2014. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000 Index and includes approximately 1000 of the largest securities based on a combination of their market cap and current index membership.

Senior Notes Offerings, Study Findings, Recognitions, Accreditations, and Collaborations - Analyst Notes on Tenet, Hologic, PAREXEL, Centene and Alnylam
PR Newswire - Mon Jun 30, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Tenet Healthcare Corp (NYSE: THC), Hologic, Inc. (NASDAQ: HOLX), PAREXEL International Corporation (NASDAQ: PRXL), Centene Corp (NYSE: CNC) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4251-100free.

Look for Shares of Alnylam Pharmaceuticals to Potentially Rebound after Yesterday's 3.73% Sell Off
Comtex SmarTrend(R) - Thu Jun 26, 5:38PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $64.08 to a high of $67.49. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $65.08 on volume of 821,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 146

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 54

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
Satellite NTN's $3.22B Promise Needs Real Receipts

Updated Category News Views 17

Dead zones over oceans, deserts, and flight paths are finally becoming a serious commercial problem, not merely a neat engineering demo. That is the muscle behind the satellite non-terrestrial network, or NTN, pitch: connect aircraft, vessels, remote assets, and scattered sensors where terrestrial networks simply do not reach. MarketsandMarkets projects this market will...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 135

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
Zoomcar's November 23 Report Puts Execution on Trial

Updated Category News Views 73

A Date on the Board, Not a Verdict November 23 is when Zoomcar finally has to put some fresh numbers beside the story. The Bengaluru-based peer-to-peer car-sharing marketplace says it will release second-quarter fiscal 2027 financial and operating results that Monday, covering the quarter ended September 30, 2026. Management also plans a live webcast at 8:00 a.m. Eastern...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 142

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
LLCP Backs Empower in UK Infrastructure Services Push

Updated Category News Views 144

A majority cheque has landed in a business built around unglamorous work that cannot be wished away: keeping mechanical and electrical systems installed, refurbished and maintained. On November 18, LLCP said it completed a majority investment in London-headquartered Empower Technical Services alongside chief executive Nicholas Manning, co-founders Florian Kronawitter and...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 41

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 95

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Elanco’s $600 Million Buyback Signals a New Chapter

Updated Category News Views 52

Debt coming down and cash coming in finally gave Elanco room to breathe. On Nov. 19, 2026, the animal-health company authorized its first-ever share repurchase program, allowing up to $600 million of common-stock purchases. For NYSE: ELAN, this is more than a flashy capital-return headline. It marks a shift from the ugly but necessary job of balance-sheet repair toward a...

Continue Reading

Top 5 Most Recently Viewed Articles

NN, Inc. Welcomes Tim Erro as Chief Commercial Officer

Updated Category News Views 219

NN, Inc. Welcomes Tim Erro as Chief Commercial Officer NN, Inc. (NASDAQ: NNBR), a leader in high-precision industrial components, has recently appointed Tim Erro as its new Chief Commercial Officer. In this role, Mr. Erro will spearhead NN's global commercial efforts, enhancing the company's strategic initiatives aimed at business growth and development. Under the...

Continue Reading
Horizon Robotics Unveils Innovations in Smart Driving Solutions

Updated Category News Views 321

Horizon Robotics Unveils Innovations at IAA Mobility 2025 Horizon Robotics, a pioneer in smart driving solutions for passenger vehicles, recently demonstrated its cutting-edge technologies at IAA Mobility 2025. This platform not only highlights the company's dedication to smart mobility but also marks a significant step in its global outreach by establishing new...

Continue Reading
Nuvoton Technology Unveils Exciting New Industrial ICs

Updated Category News Views 157

Nuvoton Technology's Innovative BM-ICs for Industrial Applications Nuvoton Technology Corporation Japan (NTCJ) is set to introduce groundbreaking industrial battery monitoring integrated circuits (BM-ICs) designed for 48V batteries. These new products, named "KA49701A" and "KA49702A," are scheduled to enter mass production soon. Enhanced Safety Features in Battery System...

Continue Reading
Celebrate National Coffee Day with Atlas Coffee Club's Free Offer

Updated Category News Views 206

Celebrate National Coffee Day with Atlas Coffee Club Atlas Coffee Club is thrilled to celebrate National Coffee Day with a fantastic offer that every coffee lover is sure to appreciate. From now until October 2, you can snag a complimentary 12-ounce bag of single-origin coffee just by subscribing. All you need to do is cover the shipping fee, and you’re all set! The...

Continue Reading
Crypto Market Dynamics: Bitcoin and XRP Show Potential Gains

Updated Category News Views 264

Bitcoin Approaches Key Resistance Levels Recently, Bitcoin has seen a substantial surge as it has crossed a significant resistance level around $102,000, signifying a bullish sentiment in the market. This progression highlights a critical test as Bitcoin now looks to penetrate a key psychological and technical barrier at $105,000. The macroeconomic backdrop is favorable,...

Continue Reading